Fresh Win For AstraZeneca/Merck & Co Pact With Koselugo Approval
First Medicine In EU For Rare Condition NF1
Executive Summary
Koselugo (selumetinib) was largely forgotten after failing Phase III trials in thyroid and lung cancer, as well as uveal melanoma, but its approval in Europe for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1, which follows a US approval for the rare condition last year, has breathed new life into the once-lauded MEK 1/2 inhibitor.
You may also be interested in...
SpringWorks Hopes Pediatric Plus Adult Data Make Mirdametinib Go-To For NF1-PN
The company plans to file for FDA approval in the first half of 2024 as it eyes a market of about 40,000 adult and pediatric patients in the US.
Keeping Track: US FDA Approves Koselugo, Bestows BTDs On Bavencio, Sotatercept
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
AstraZeneca agreed to partner two important oncology assets – Lynparza and selumetinib – with Merck after disappointing Imfinzi MYSTIC data. Merck will pay $1.6bn up front to get its hands on a PARP inhibitor, even though it previously owned one.